Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.65 |
| ▸ | MMP9 | P14780 | 7/20 | 0.65 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.65 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297543 | 1.00 | MMP2 (0.65) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL286031 | 0.86 | MEN1 (0.63) | MMP2MMP9ADAMTS4MMECA2 | |
| SCHEMBL286032 | 0.86 | MEN1 (0.63) | MMP2MMP9ADAMTS4MMECA2 | |
| Benzene SCHEMBL28198278 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL698062 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL698061 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL4316657 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL4732686 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL6436714 | 0.84 | MMP2 (0.63) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL6653310 | 0.83 | MMP1 (0.52) | MMP2MMP9ADAMTS4MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604536-A | HER2 binding agents and uses thereof | 塞雷乌斯股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118176024-A | Reagents for site-specific labelling of proteins with radiohalogen, and methods of making and using the same | 杜克大学 | 2024-06-11 | — | — | CN | claimed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| EP-4117732-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Ambrx, Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. | 2022-07-21 | — | — | US | claimed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2021183832-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| EP-3844188-A1 | ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2021-07-07 | — | — | EP | claimed |
| CN-112646002-A | Sulfoamino acid modified antioxidant oligopeptide and preparation thereof | 浙江海洋大学 | 2021-04-13 | — | — | CN | claimed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| WO-2020047176-A1 | ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES | AMBRX, INC. (US) | 2020-03-05 | — | — | WO | claimed |
| CN-110709106-A | Radiolabeled biomolecules and uses thereof | 杜克大学 | 2020-01-17 | — | — | CN | claimed |
| EP-0443598-B1 | Peptides inhibiting the blood coagulation, their process of preparation and their use | BEHRINGWERKE AG (DE) | 1995-05-17 | — | — | EP | claimed |
| EP-0443598-A2 | Peptides inhibiting the blood coagulation, their process of preparation and their use | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-08-28 | — | — | EP | claimed |
| CN-119604536-A | HER2 binding agents and uses thereof | 塞雷乌斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-118176024-A | Reagents for site-specific labelling of proteins with radiohalogen, and methods of making and using the same | 杜克大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-0739338-A1 | NOVEL SERINE PROTEASE INHIBITORS: DERIVATIVES OF ISOTHIAZOLIDIN-3-ONE-1,1 DIOXIDE AND 3-OXO-1,2,5-THIADIAZOLIDINE-1,1-DIOXIDE | THE WICHITA STATE UNIVERSITY (US) | 1996-10-30 | — | — | EP | disclosed |
| US-5550139-A | ANTIINFLAMMATORY AGENT, ANTITUMOR AGENT, ANTICARCINOGENIC AGENT | THE WICHITA STATE UNIVERSITY (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1995018797-A1 | NOVEL SERINE PROTEASE INHIBITORS: DERIVATIVES OF ISOTHIAZOLIDIN-3-ONE-1,1 DIOXIDE AND 3-OXO-1,2,5-THIADIAZOLIDINE-1,1-DIOXIDE | THE WICHITA STATE UNIVERSITY (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | TLR1, TLR3, TLR2 | MMP2 3843/4885MMP9 3957/4885ADAMTS4 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.